White matter lesions and the cholinergic deficit in aging and mild cognitive impairment

Neurobiology of Aging

Volumn 53, Issue , 2017, Pages 27-35

  Richter, Nils ^a,b,c   Michel, Anne ^a,d   Onur, Oezguer A ^a,b   Kracht, Lutz ^a,c   Dietlein, Markus ^a   Tittgemeyer, Marc ^c   Neumaier, Bernd ^a,b   Fink, Gereon R ^a,b   Kukolja, Juraj ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^d ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Acetylcholinesterase; MP4A; PET

Indexed keywords

ACETIC ACID; ACETYLCHOLINESTERASE; N METHYL 4 PIPERIDYL ACETATE; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; N-METHYL-4-PIPERIDYL ACETATE; PIPERIDINE DERIVATIVE;

ADULT; AGE; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; AUTONOMIC NEUROPATHY; BRAIN ATROPHY; CHOLINERGIC ACTIVITY; CHOLINERGIC DEFICIT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GRAY MATTER; HUMAN; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; VERY ELDERLY; WHITE MATTER LESION; COGNITIVE DEFECT; COMPLICATION; DIAGNOSTIC IMAGING; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGY; WHITE MATTER;

ACETATES; ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; WHITE MATTER;

EID: 85012195352     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2017.01.012     Document Type: Article

References (70)

1. Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Thies, B., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 270–279.
2. Bartus, R.T., Physostigmine and recent memory: effects in young and aged nonhuman primates. Science 206 (1979), 1087–1089.
3. Bartus, R.T., Dean, R.L., Beer, B., Lippa, A.S., The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982), 408–414.
4. Berger-Sweeney, J., Heckers, S., Mesulam, M.M., Wiley, R.G., Lappi, D.A., Sharma, M., Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis. J. Neurosci. 14 (1994), 4507–4519.
5. Berres, M., Monsch, A.U., Bernasconi, F., Thalmann, B., Stähelin, H.B., Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease. Stud. Health Technol. Inform. 77 (2000), 195–199.
6. Bohnen, N.I., Kaufer, D.I., Hendrickson, R., Ivanco, L.S., Lopresti, B., Davis, J.G., Constantine, G., Mathis, C.A., Moore, R.Y., DeKosky, S.T., Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci. Lett. 380 (2005), 127–132.
7. Bohnen, N.I., Müller, M.L., Kuwabara, H., Constantine, G.M., Studenski, S.A., Age-associated leukoaraiosis and cortical cholinergic deafferentation. Neurology 72 (2009), 1411–1416.
8. Bolandzadeh, N., Davis, J.C., Tam, R., Handy, T.C., Liu-Ambrose, T., The association between cognitive function and white matter lesion location in older adults: a systematic review. BMC Neurol., 12, 2012, 126.
9. Cole, D.A., Maxwell, S.E., Testing mediational models with longitudinal data: questions and tips in the use of structural equation modeling. J. Abnorm. Psychol. 112 (2003), 558–577.
10. Davies, P., Maloney, A.J., Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 2, 1976, 1403.
11. Davis, K.L., Mohs, R.C., Tinklenberg, J.R., Enhancement of memory by physostigmine. N. Engl. J. Med., 301, 1979, 946.
12. De Groot, J.C., De Leeuw, F.E., Oudkerk, M., Van Gijn, J., Hofman, A., Jolles, J., Breteler, M.M., Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann. Neurol. 52 (2002), 335–341.
13. Debette, S., Bombois, S., Bruandet, A., Delbeuck, X., Lepoittevin, S., Delmaire, C., Leys, D., Pasquier, F., Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. Stroke 38 (2007), 2924–2930.
14. DeCarli, C., Murphy, D.G., Tranh, M., Grady, C.L., Haxby, J.V., Gillette, J.A., Salerno, J.A., Gonzales-Aviles, A., Horwitz, B., Rapoport, S.I., The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 45 (1995), 2077–2084.
15. Dickerson, B.C., Eichenbaum, H., The episodic memory system: neurocircuitry and disorders. Neuropsychopharmacology 35 (2010), 86–104.
16. Drachman, D.A., Leavitt, J., Human memory and the cholinergic system. A relationship to aging?. Arch. Neurol. 30 (1974), 113–121.
17. Duits, F.H., Teunissen, C.E., Bouwman, F.H., Visser, P.J., Mattsson, N., Zetterberg, H., Blennow, K., Hansson, O., Minthon, L., Andreasen, N., Marcusson, J., Wallin, A., Rikkert, M.O., Tsolaki, M., Parnetti, L., Herukka, S.K., Hampel, H., De Leon, M.J., Schröder, J., Aarsland, D., Blankenstein, M.A., Scheltens, P., van der Flier, W.M., The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean?. Alzheimers Dement 10 (2014), 713–723.e2.
18. Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., Damaraju, C.V., Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359 (2002), 1283–1290.
19. Fink, G.R., Markowitsch, H.J., Reinkemeier, M., Bruckbauer, T., Kessler, J., Heiss, W.D., Cerebral representation of one's own past: neural networks involved in autobiographical memory. J. Neurosci. 16 (1996), 4275–4282.
20. Fritz, M.S., Mackinnon, D.P., Required sample size to detect the mediated effect. Psychol. Sci. 18 (2007), 233–239.
21. Galani, R., Lehmann, O., Bolmont, T., Aloy, E., Bertrand, F., Lazarus, C., Jeltsch, H., Cassel, J.C., Selective immunolesions of CH4 cholinergic neurons do not disrupt spatial memory in rats. Physiol. Behav. 76 (2002), 75–90.
22. Gu, Y., Vorburger, R.S., Gazes, Y., Habeck, C.G., Stern, Y., Luchsinger, J.A., Manly, J.J., Schupf, N., Mayeux, R., Brickman, A.M., White matter integrity as a mediator in the relationship between dietary nutrients and cognition in the elderly. Ann. Neurol. 79 (2016), 1014–1025.
23. Haense, C., Kalbe, E., Herholz, K., Hohmann, C., Neumaier, B., Krais, R., Heiss, W.D., Cholinergic system function and cognition in mild cognitive impairment. Neurobiol. Aging 33 (2012), 867–877.
24. Hattori, N., Movement disorders: advances in 2015. Lancet Neurol. 15 (2016), 8–9.
25. Helmstaedter, C., Lendt, M., Lux, S., Verbaler Lern- und Merkfähigkeitstest. 2001, Beltz Test GmbH, Göttingen.
26. Herholz, K., Bauer, B., Wienhard, K., Kracht, L., Mielke, R., Lenz, M.O., Strotmann, T., Heiss, W.D., In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J. Neural. Transm. 107 (2000), 1457–1468.
27. Herholz, K., Lercher, M., Wienhard, K., Bauer, B., Lenz, O., Heiss, W.D., PET measurement of cerebral acetylcholine esterase activity without blood sampling. Eur. J. Nucl. Med. 28 (2001), 472–477.
28. Herholz, K., Weisenbach, S., Zündorf, G., Lenz, O., Schröder, H., Bauer, B., Kalbe, E., Heiss, W.D., In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 21 (2004), 136–143.
29. Hindmarch, I., Lehfeld, H., de Jongh, P., Erzigkeit, H., The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr. Cogn. Disord. 9:Suppl 2 (1998), 20–26.
30. Horn, W., L-p-s Leistungsprüfsystem. 1983, Hogrefe, Göttingen.
31. Jellinger, K.A., Clinicopathological analysis of dementia disorders in the elderly–an update. J. Alzheimers Dis. 9:3 Suppl (2006), 61–70.
32. Kim, H., Neural activity that predicts subsequent memory and forgetting: a meta-analysis of 74 fMRI studies. Neuroimage 54 (2011), 2446–2461.
33. Kim, S., Choi, S.H., Lee, Y.M., Kim, M.J., Kim, Y.D., Kim, J.Y., Park, J.H., Myung, W., Na, H.R., Han, H.J., Shim, Y.S., Kim, J.H., Yoon, S.J., Kim, S.Y., Kim, D.K., Periventricular white matter hyperintensities and the risk of dementia: a CREDOS study. Int. Psychogeriatr. 27 (2015), 2069–2077.
34. Kukolja, J., Thiel, C.M., Wilms, M., Mirzazade, S., Fink, G.R., Ageing-related changes of neural activity associated with spatial contextual memory. Neurobiol. Aging 30 (2009), 630–645.
35. Lee, H.K., Lee, Y.M., Park, J.M., Lee, B.D., Moon, E.S., Chung, Y.I., Amnestic multiple cognitive domains impairment and periventricular white matter hyperintensities are independently predictive factors progression to dementia in mild cognitive impairment. Int. J. Geriatr. Psychiatry 29 (2014), 526–532.
36. Luchsinger, J.A., Brickman, A.M., Reitz, C., Cho, S.J., Schupf, N., Manly, J.J., Tang, M.X., Small, S.A., Mayeux, R., DeCarli, C., Brown, T.R., Subclinical cerebrovascular disease in mild cognitive impairment. Neurology 73 (2009), 450–456.
37. Marcone, A., Garibotto, V., Moresco, R.M., Florea, I., Panzacchi, A., Carpinelli, A., Virta, J.R., Tettamanti, M., Borroni, B., Padovani, A., Bertoldo, A., Herholz, K., Rinne, J.O., Cappa, S.F., Perani, D., [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer's disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. J. Alzheimers Dis. 31 (2012), 387–399.
38. Menard, S., Applied Logistic Regression Analysis: Sage University Series on Quantitative Applications in the Social Sciences. 1995, Sage, Thousand Oaks.
39. Mesulam, M., The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn Mem. 11 (2004), 43–49.
40. Mesulam, M., Siddique, T., Cohen, B., Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 60 (2003), 1183–1185.
41. Minoshima, S., Frey, K.A., Koeppe, R.A., Foster, N.L., Kuhl, D.E., A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 36 (1995), 1238–1248.
42. Mohs, R.C., Doody, R.S., Morris, J.C., Ieni, J.R., Rogers, S.L., Perdomo, C.A., Pratt, R.D., Group, S., A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 (2001), 481–488.
43. Murray, M.E., Senjem, M.L., Petersen, R.C., Hollman, J.H., Preboske, G.M., Weigand, S.D., Knopman, D.S., Ferman, T.J., Dickson, D.W., Jack, C.R., Functional impact of white matter hyperintensities in cognitively normal elderly subjects. Arch. Neurol. 67 (2010), 1379–1385.
44. Namba, H., Iyo, M., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., Sudo, Y., Suzuki, K., Irie, T., Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age. Eur. J. Nucl. Med. 26 (1999), 135–143.
45. Osterrieth, P., The test of copying a complex figure: a contribution to the study of perception and memory. Arch. de Psychol. 30 (1944), 206–356.
46. Parent, M.B., Baxter, M.G., Septohippocampal acetylcholine: involved in but not necessary for learning and memory?. Learn Mem. 11 (2004), 9–20.
47. Pawlak, M., Krejza, J., A new visual scale to assess white matter hyperintensities within cholinergic pathways. Stroke 36 (2005), 2064–2065.
48. Perry, E.K., Gibson, P.H., Blessed, G., Perry, R.H., Tomlinson, B.E., Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 34 (1977), 247–265.
49. Petersen, R.C., Thomas, R.G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., Pfeiffer, E., Sano, M., van Dyck, C.H., Thal, L.J., Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352 (2005), 2379–2388.
50. Pratt, R.D., Perdomo, C.A., Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann. N. Y. Acad. Sci. 977 (2002), 513–522.
51. Preacher, K.J., Hayes, A.F., Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav. Res. Methods 40 (2008), 879–891.
52. Prins, N.D., Scheltens, P., White matter hyperintensities, cognitive impairment and dementia: an update. Nat. Rev. Neurol. 11 (2015), 157–165.
53. Raschetti, R., Albanese, E., Vanacore, N., Maggini, M., Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med., 4, 2007, e338.
54. Reitan, R.M., Trail Making Test: Manual for Administration, Scoring and Interpretation. 1956, Indiana University Press, Indianapolis.
55. Rey, A., L'examen clinique en psychologie. 1964, Presses Universitaires de France, Paris.
56. Richter, N., Allendorf, I., Onur, O.A., Kracht, L., Dietlein, M., Tittgemeyer, M., Neumaier, B., Fink, G.R., Kukolja, J., The integrity of the cholinergic system determines memory performance in healthy elderly. Neuroimage 100 (2014), 481–488.
57. Scheltens, P., Barkhof, F., Leys, D., Pruvo, J.P., Nauta, J.J., Vermersch, P., Steinling, M., Valk, J., A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J. Neurol. Sci. 114 (1993), 7–12.
58. Scheltens, P., Leys, D., Barkhof, F., Huglo, D., Weinstein, H.C., Vermersch, P., Kuiper, M., Steinling, M., Wolters, E.C., Valk, J., Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J. Neurol. Neurosurg. Psychiatry 55 (1992), 967–972.
59. Schmitt, M., Altstötter-Gleich, C., Hinz, A., Maes, J., Brähler, E., Normwerte für das Vereinfachte Beck Depressions-Inventar (BDI-V) in der Allgemeinbevölkerung. Diagnostica 52 (2006), 51–59.
60. Schretlen, D.J., Bobholz, J.H., Brandt, J., Development and psychometric properties of the brief test of attention. Clin. Neuropsychologist 10 (1996), 80–89.
61. Selden, N.R., Gitelman, D.R., Salamon-Murayama, N., Parrish, T.B., Mesulam, M.M., Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121:Pt 12 (1998), 2249–2257.
62. Shinotoh, H., Namba, H., Fukushi, K., Nagatsuka, S., Tanaka, N., Aotsuka, A., Ota, T., Tanada, S., Irie, T., Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann. Neurol. 48 (2000), 194–200.
63. Smith, E.E., Salat, D.H., Jeng, J., McCreary, C.R., Fischl, B., Schmahmann, J.D., Dickerson, B.C., Viswanathan, A., Albert, M.S., Blacker, D., Greenberg, S.M., Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology 76 (2011), 1492–1499.
64. van den Heuvel, D.M., ten Dam, V.H., de Craen, A.J., Admiraal-Behloul, F., Olofsen, H., Bollen, E.L., Jolles, J., Murray, H.M., Blauw, G.J., Westendorp, R.G., van Buchem, M.A., Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J. Neurol. Neurosurg. Psychiatry 77 (2006), 149–153.
65. van Straaten, E.C., Harvey, D., Scheltens, P., Barkhof, F., Petersen, R.C., Thal, L.J., Jack, C.R., DeCarli, C., Alzheimer's Disease Cooperative Study Group. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J. Neurol. 255 (2008), 1302–1308.
66. Villeneuve, S., Reed, B.R., Wirth, M., Haase, C.M., Madison, C.M., Ayakta, N., Mack, W., Mungas, D., Chui, H.C., DeCarli, C., Weiner, M.W., Jagust, W.J., Cortical thickness mediates the effect of β-amyloid on episodic memory. Neurology 82 (2014), 761–767.
67. Wenk, G.L., Stoehr, J.D., Quintana, G., Mobley, S., Wiley, R.G., Behavioral, biochemical, histological, and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats. J. Neurosci. 14 (1994), 5986–5995.
68. Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.L., Zhang, R., Haglund, A., Subbiah, P., Group, D.N.S., A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001), 489–495.
69. Zu, A.D., Wumbo, B.D., Understanding and using mediators and moderators. Soc. Indic Res. 87 (2008), 367–392.
70. Zundorf, G., Herholz, K., Lercher, M., Wienhard, K., Bauer, B., Weisenbach, S., Weiss, W.D., PET functional parametric images of acetylcholine esterase activity without blood sampling. Senda, M., Kimura, Y., Herscovitch, P., (eds.) Brain Imaging Using PET, 2002, Academic Press, San Diego, 41–46.